ArticleAbdominal radiology (New York)2026
Common bile duct dilatation on MRI in autosomal dominant polycystic kidney disease.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolycystic liver disease is the most prevalent extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Non-obstructive asymptomatic common bile duct (CBD) dilatation has been observed anecdotally on CT scans, but CT is not optimal for biliary visualization. Here, we measured CBD diameter on T2-weighted MRI in ADPKD subjects to determine if CBD dilatation is associated with ADPKD.
methodsCBD diameter was measured retrospectively on ADPKD subjects (n = 254) and on age- and sex-matched controls without ADPKD (n = 254) who underwent abdominal MRI. CBD diameter in these groups was compared and correlated with clinical, laboratory and magnetic resonance imaging (MRI) features, including organ volumes and cyst burden.
resultsCBD median diameter [interquartile range, IQR, 25%, 75%] was 22% larger in ADPKD compared to controls (5.6 [4.7, 6.9] mm vs. 4.6 [3.9, 5.4] mm, p < 0.001). CBD diameter measurements had excellent inter-observer agreement (Intraclass correlation coefficient = 0.92). Thirteen (5.1%) ADPKD subjects had a CBD diameter ≥ 10 mm compared to 1 (0.4%) control subject (p < 0.001). Multivariable analysis found the presence of PKD1 or PKD2 mutation (beta = 1.5, P < 0.001) and age (beta = 0.04, p < 0.001) to be associated with increased CBD diameter and serum albumin associated with decreased CBD diameter (beta=-0.39, p < 0.001).
conclusionADPKD subjects had 22% larger CBD diameters than in non-ADPKD controls and were more likely to have CBD dilatation ≥ 10 mm without CBD obstruction. Awareness of this association of non-obstructive CBD dilatation with ADPKD may limit unnecessary diagnostic testing.
Indexed as
Identifiers
40676196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.